The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim +17 more
wiley +1 more source
Environmental volatility is associated with adaptive caution in visual search. [PDF]
Qiu N +4 more
europepmc +1 more source
Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim +11 more
wiley +1 more source
Is it time to retire bolus cisplatin? Lessons from the ConCERT trial. [PDF]
Merkin RD, Bhatia A.
europepmc +1 more source
Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba +5 more
wiley +1 more source
Methodological concerns limiting the detection of treatment effects in the OSAN trial of blue-blocking glasses for mania. [PDF]
Henriksen TEG +12 more
europepmc +1 more source
Comment on "Transcutaneous Electrical Acupoint Stimulation to Prevent Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Surgery: A Multicenter Randomized Controlled Trial Protocol" [Letter]. [PDF]
Hong C, Zhang Q.
europepmc +1 more source
PaSo paracetamol with strong opioids trial: paracetamol versus placebo in conjunction with strong opioids for cancer pain-a pilot randomised placebo-controlled withdrawal trial. [PDF]
Hagen KMR +5 more
europepmc +1 more source
Personalised approach to venous thromboembolism prophylaxis in heavier critically ill patients (PROSPER): A randomised, parallel-group, electronic medical record (EMR)-embedded feasibility trial. [PDF]
Ali Abdelhamid Y +12 more
europepmc +1 more source

